Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, AstraZeneca Partner on Oncology Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies today announced a collaboration with AstraZeneca in support of one of its oncology programs.

Under the terms of the deal, Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale, it said in a statement. Information from the analyses is anticipated to provide insight into the cellular functions of potential drug targets.

Financial and other terms of the deal were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.